Y-90 Radioembolization Radiation Safety

Introduction

Yttrium-90 radioembolization is a pure beta-emitting therapy, and that single fact reshapes its entire radiation safety program. There is no primary gamma ray to shield against with lead walls; instead the program turns on contamination control, extremity dose to the hands, correct dose assay, and low-atomic-number shielding. A safety plan copied from a gamma-emitting therapy will get the physics — and the priorities — wrong. ^{1, 5}

Y-90 radioembolization, also called selective internal radiation therapy (SIRT) or transarterial radioembolization (TARE), delivers millions of radioactive microspheres through a catheter in the hepatic artery so they lodge in the microvasculature of liver tumors and irradiate them from within. It is a multidisciplinary procedure — interventional radiology, nuclear medicine, radiation oncology, and medical physics all have roles — and the radiation safety officer (RSO) and medical physicist own the parts that keep staff, the public, and the environment protected. ^{5, 11}

This guide explains Y-90's decay physics and why it drives an unusual safety posture, how shielding and contamination control differ from gamma work, the dose-assay and post-procedure survey workflow, patient release, and the NRC and Agreement State framework that makes the program defensible. DRPS supports these programs through its radiation safety officer, radioactive material license support, and PET/CT and nuclear medicine physics services.

Topic Explanation

What is Y-90 radioembolization?

Y-90 radioembolization is a locoregional liver-cancer treatment in which Y-90-loaded glass or resin microspheres are infused into the hepatic arterial supply of a tumor to deliver a high, spatially confined radiation dose. Because the spheres embolize in tumor microvasculature and the beta range is short, the dose is concentrated in the tumor while surrounding liver is relatively spared. ^{5, 8}

Two microsphere products dominate practice:

Glass microspheres (TheraSphere) — higher activity per sphere, lower embolic load, and a widely used personalized dosimetry framework. ⁸
Resin microspheres (SIR-Spheres) — lower activity per sphere, more spheres per dose, and a higher embolic load; recent trials use personalized dosimetry targeting a mean tumor dose on the order of ≥150 Gy. ⁹

The workup includes a technetium-99m macroaggregated albumin (Tc-99m MAA) mapping study to quantify the lung shunt fraction and characterize hepatic vascular supply before the Y-90 dose is ordered. ⁵ The therapy dosimetry side of this — tumor and lung dose calculation — is covered in our companion post on Y-90 radioembolization dosimetry; the present article focuses on the radiation safety program that surrounds the procedure.

Why the physics dictates the safety posture

Almost everything unusual about Y-90 radiation safety flows from one property: it is essentially a pure beta emitter with no primary gamma. That means the penetrating external hazard that dominates gamma therapies is largely absent, and the hazards that remain — skin and extremity dose from close handling, and contamination from a liquid radioactive source — move to the front. The corollary is that the tools change too: low-Z shielding instead of lead, contamination instruments and bremsstrahlung detection instead of a gamma-only survey, and immediate patient release instead of prolonged isolation. ^{1, 5}

Key Technical Principles

Y-90 decay: pure beta, no primary gamma

Yttrium-90 decays to stable zirconium-90 with a physical half-life of about 64.05 hours (2.67 days), emitting beta particles with a maximum energy of about 2.28 MeV and a mean energy of about 0.93 MeV. It has essentially no primary gamma emission. Two secondary radiations matter for safety and imaging: bremsstrahlung X-rays produced as the energetic betas decelerate in tissue and materials, and a very rare internal pair-production branch (on the order of 32 parts per million) that yields 511 keV photons and makes Y-90 PET imaging possible. ^{1, 12}

Emission	Origin	Radiation-safety implication
Beta particles (β⁻, max ~2.28 MeV)	Primary Y-90 decay	Therapeutic; short range (~11 mm in tissue); stopped by ~1 cm of low-Z plastic; drives contamination and extremity-dose concern, not room shielding
Bremsstrahlung X-rays	Betas decelerating in tissue and materials	Low-level penetrating photons; basis for post-therapy SPECT/bremsstrahlung imaging and survey detection; worsened by high-Z shielding
511 keV annihilation photons	Rare internal pair production (~32 ppm)	Enables Y-90 PET imaging; negligible contribution to external dose

Beta range and why shielding is low-Z

The therapeutic betas are energetic but short-range. The maximum range of a beta particle can be estimated from the Katz-Penfold empirical relation for energies above about 0.8 MeV:

R_{m a x} = 0.542 E_{β, m a x} - 0.133 [g/cm^{2}]

For Y-90's maximum beta energy of 2.28 MeV:

R_{m a x} = 0.542 \times 2.28 - 0.133 \approx 1.10 g/cm^{2}

Converting to thickness by dividing by material density: in soft tissue or water (ρ ≈ 1.0 g/cm³) that is about 11 mm, and in acrylic (PMMA, ρ ≈ 1.19 g/cm³) it is:

t = \frac{1.10 g/cm ^{2}}{1.19 g/cm ^{3}} \approx 0.93 cm \approx 9.3 mm

So roughly one centimeter of acrylic stops essentially all Y-90 betas. This is why syringe shields, vial shields, and bench barriers for Y-90 are made of low-atomic-number plastic. Using lead as the first line of beta shielding is a mistake: high-Z materials increase bremsstrahlung X-ray yield, so a lead shield in front of the source can produce more penetrating photons than the unshielded beta source would. The correct order, when any lead is used at all, is beta-stopping plastic first, then lead behind it to attenuate the residual bremsstrahlung. ⁵

Dose assay and delivered-activity determination

Because the microspheres carry the therapeutic dose, the assay of activity is a radiation-safety and quality function, not just a clinical one. The Y-90 activity is measured before administration in a dose calibrator with a calibration traceable to a national standard, and the delivered activity is determined from the difference between the pre-treatment activity and the residual left in the vial, tubing, and delivery apparatus after the infusion — typically from the ratio of pre-treatment and residual exposure-rate measurements. The delivered activity is then recorded against the written directive. ⁵

This residual-based determination is essential because a nontrivial fraction of activity can remain in the delivery set, and the patient's record must reflect what was actually administered, not what was ordered.

Clinical Impact

A correct understanding of Y-90's physics makes the program simpler in some ways and stricter in others. It is simpler because there is no need for heavy structural shielding or prolonged patient isolation; it is stricter because contamination control and dose determination carry more of the safety load. ^{1, 5}

External dose rates from a treated patient are strikingly low. In a single-center series of 212 outpatients, the mean ambient dose rate at one meter after Y-90 microsphere administration was about 1.88 ± 0.74 µSv/h (range 0.2–4.3 µSv/h), comfortably below the ~5 µSv/h threshold used for outpatient treatment, and serious adverse events requiring hospitalization occurred in only 3.3% of patients — confirming that radioembolization is safely delivered as an outpatient procedure. ⁶ Operator exposure is likewise modest when technique is good; a preclinical model study measured mean operator extremity exposure of about 41.7 µSv per infusion, underscoring that the hands — closest to the source — are the relevant dose site, which is why ring (extremity) dosimeters are worn. ⁷

The safety implications for a program are concrete:

The hands are the dose site. Extremity dosimetry, distance, and low-Z shielding protect the operator far more than room design. ⁷
Contamination is the residual hazard. The source is a liquid suspension delivered through a catheter set; spills, back-flow, and contaminated waste are the realistic failure modes. ⁵
Patients go home. Low external dose rates support immediate release under 10 CFR 35.75 with brief written instructions. ¹⁰
Waste decays fast. With a 64-hour half-life, decay-in-storage clears most Y-90 waste within weeks. ⁵

Because radioembolization is increasingly combined with systemic anticancer therapy, programs should also be aware of multidisciplinary consensus guidance on the safety of those combinations, even though the sequencing decisions themselves belong to the treating oncology and IR teams. ¹⁰ The shielding and handling logic here parallels our discussion of RPT shielding for Lu-177, Ra-223, and Ac-225, where the radionuclide — not a generic template — sets the safety approach.

Practical Optimization Tips

A defensible Y-90 radioembolization safety program is built from a repeatable set of controls.

1. Shield low-Z, and in the right order

Use acrylic syringe and vial shields and a benchtop beta barrier for dose preparation and handling. If lead is used to attenuate bremsstrahlung, place it behind the acrylic, never in front. Keep about a centimeter of plastic between hands and any unshielded source. ⁵

2. Wear — and read — extremity dosimetry

Staff who handle the dose should wear ring (extremity) dosimeters in addition to whole-body badges, positioned to capture the highest-dose point on the hand. Review extremity results against occupational limits and investigate outliers. ⁷

3. Post and control the treatment suite

During the procedure, post the suite as a radioactive area, restrict access, and confirm that survey and contamination instruments are present and functioning. Prepare a dedicated area for delivery-set handling and waste. ⁵

4. Assay correctly and determine residual

Assay the dose in a dose calibrator calibrated traceable to a national standard, and after the procedure determine the delivered activity from the pre-treatment and residual measurements. Record it against the written directive. ⁵

5. Survey and manage waste

After the procedure, survey the room, patient, and staff, and check for contamination of the floor, table, and delivery pathway. Collect all Y-90 waste — vials, tubing, catheters, pads, gloves — and manage it by decay-in-storage, then survey before disposal to confirm it has decayed to background. ⁵

6. Have a spill plan

Prepare for the realistic contamination scenario: a back-flow or disconnected line during infusion. Have absorbent materials, a spill kit, and a documented response procedure ready, and train staff on it before the first case.

Common pitfalls to avoid

Shielding Y-90 with lead first. High-Z shielding increases bremsstrahlung; stop the betas with plastic first.
Surveying like a gamma emitter. Y-90 needs contamination instruments and bremsstrahlung-aware detection, not a gamma-only sweep.
Skipping the residual measurement. The delivered dose is pre-treatment minus residual, and residual can be significant.
Isolating the patient unnecessarily. External dose rates are very low; patients are typically released immediately.
Ignoring the hands. Extremity dose, not whole-body dose, is usually the limiting occupational exposure.
Copying another isotope's SOP. A Lu-177 or I-131 procedure does not correctly address a pure beta emitter's hazards.

Regulatory Considerations

Y-90 microspheres are byproduct material regulated by the NRC or an Agreement State, and radioembolization is authorized under the "other medical use" provisions of 10 CFR 35.1000. Because the products are not covered by the standard modality-specific subparts, the NRC issues product-specific licensing guidance, and the general requirements of Part 35 still apply. ^{1, 2}

Key regulatory anchors:

10 CFR 35.1000 and NRC licensing guidance. Y-90 glass and resin microspheres are authorized under 35.1000, and the NRC's Yttrium-90 Microsphere Licensing Guidance sets out product-specific expectations. Licenses issued under 35.1000 must still meet the general requirements of Part 35 Subparts A, B, C, L, and M. ^{1, 2}
Written directive and its determination (10 CFR 35.40/35.41). A written directive is required before administration, and the licensee must record the activity delivered to the treatment site — hence the residual-based delivered-activity determination. See our guide to written directives in nuclear medicine. ²
10 CFR Part 20. Occupational and public dose limits, contamination control, waste, and survey requirements apply throughout. ³
Patient release (10 CFR 35.75, Reg Guide 8.39). The licensee may release a patient if the dose to any other individual is not likely to exceed 5 mSv; Y-90 microsphere patients almost always qualify for immediate release. [10, RG 8.39]
License amendment and training. Establishing the program requires a materials-license amendment, an authorized user, and product-specific training commensurate with each person's role, as described in AAPM MPPG 14.a. ⁵
Transport. Shipment and receipt of the Y-90 dose fall under DOT hazardous-materials rules; see radioactive material transport under DOT.

Jurisdiction depends on the state. Of the states DRPS serves, Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey are NRC Agreement States that license medical use under their own radiation-control programs, while Washington DC and Delaware are regulated directly by the NRC. A facility must confirm which authority issues its license, obtain the 35.1000 authorization and authorized-user approval, and align its procedures with the applicable rules before treating patients. Multidisciplinary practice parameters from the ACR, ABS, ACNM, ARS, SIR, and SNMMI provide additional consensus expectations for the program. ¹¹

Frequently Asked Questions (FAQs)

Why is Y-90 radiation safety different from other radiopharmaceutical therapies?

Yttrium-90 is a pure beta emitter with no primary gamma ray. Its therapeutic radiation is short-range beta particles that are stopped by about a centimeter of low-atomic-number plastic, so the dominant concerns are contamination control, extremity dose to the hands, and correct dose assay — not thick lead room shielding. High-Z shielding like lead is actually counterproductive because it increases bremsstrahlung X-ray production.

How is Y-90 microsphere radioembolization regulated?

Y-90 glass and resin microspheres are regulated by the NRC (or an Agreement State) under 10 CFR 35.1000 for other medical uses of byproduct material, with the general requirements of 10 CFR Part 35 Subparts A, B, C, L, and M and the protection standards of 10 CFR Part 20 also applying. The facility needs a license amendment, an authorized user, a written directive, and product-specific training before performing treatments.

What shielding is used for Y-90?

Low-atomic-number materials such as acrylic (PMMA) are used because they stop beta particles while producing minimal bremsstrahlung. About one centimeter of acrylic stops essentially all Y-90 betas. Lead is avoided as primary beta shielding because high-Z materials generate more bremsstrahlung X-rays; if any lead is used, it goes behind the acrylic, not in front of it.

Can Y-90 radioembolization patients be released right after treatment?

Yes, in almost all cases. Because Y-90 emits no primary gamma and the microspheres lodge in the liver, external dose rates from the patient are very low — published measurements report on the order of about 2 microsieverts per hour at one meter. The dose to others is well below the 5 mSv limit in 10 CFR 35.75, so patients are typically released immediately with brief written instructions.

How is the delivered Y-90 dose determined for the record?

The activity is assayed before administration in a dose calibrator with a calibration traceable to a national standard, and the delivered activity is determined from the difference between the pre-treatment measurement and the residual activity left in the vial, tubing, and waste after the procedure — typically from the ratio of pre-treatment and residual exposure-rate measurements. This delivered activity is recorded against the written directive.

What surveys are required after a Y-90 procedure?

After the procedure the treatment room, the patient, and staff are surveyed, and all Y-90 waste — vials, tubing, catheters, absorbent pads, and gloves — is contamination-controlled and managed as radioactive waste, usually by decay-in-storage given the short 64-hour half-life. Because Y-90 is a beta emitter, surveys rely on appropriate contamination instruments and on bremsstrahlung detection rather than on a standard gamma-only approach.

Key Takeaways

Y-90 is a pure beta emitter (max ~2.28 MeV, mean ~0.93 MeV, ~64-hour half-life, no primary gamma), so contamination and extremity dose — not room shielding — dominate.
Shield with low-Z plastic. About 1 cm of acrylic stops all Y-90 betas; lead first would increase bremsstrahlung and is avoided.
The hands are the dose site. Ring dosimetry, distance, and technique protect the operator more than facility design.
Assay and residual matter. Delivered activity is the pre-treatment measurement minus residual, recorded against the written directive.
Patients go home. External dose rates near ~2 µSv/h at 1 m support immediate release under 10 CFR 35.75.
The program is regulated under 10 CFR 35.1000 with a license amendment, authorized user, written directive, and NRC or Agreement State oversight.

Conclusion

Y-90 radioembolization is one of the clearest examples in medical health physics of how the radionuclide dictates the program. Because Y-90 is a pure beta emitter, the instincts carried over from gamma-emitting therapies — thick lead, prolonged isolation, gamma surveys — are not just unnecessary but partly wrong. The right program protects the hands with low-Z shielding and extremity dosimetry, controls contamination from a liquid source and its delivery set, assays and reconciles the delivered activity, surveys the room and waste, and releases the patient immediately under a documented dose assessment.

Built this way, a radioembolization safety program is both simpler and more rigorous than a naïve template: fewer structural demands, but tighter contamination and dose-determination discipline, all anchored to the 10 CFR 35.1000 authorization and the general Part 20 and Part 35 requirements. Facilities that ground the program in Y-90's actual physics will protect staff, satisfy the license, and keep the safe process the easy process for a busy interventional team.

How DRPS Can Help

Diagnostic Radiation Physics Services helps facilities establish and maintain Y-90 radioembolization programs: license-amendment and 35.1000 authorization support, RSO and authorized-user program guidance, radiation safety procedures, dose-assay and survey workflow design, contamination-control and spill planning, staff training, and post-procedure documentation review — delivered by board-certified medical physicists. Explore our radiation safety officer, radioactive material license support, and PET/CT and nuclear medicine physics services.

DRPS supports facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A radioembolization program is a health-physics program first. Get the physics right, and the rest of the safety plan follows.

Related Resources

References

U.S. Nuclear Regulatory Commission. Yttrium-90 Microsphere Brachytherapy Licensing Guidance. nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material (including 35.1000 and 35.40/35.41). nrc.gov
U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
U.S. Nuclear Regulatory Commission. Regulatory Guide 8.39: Release of Patients Administered Radioactive Material. nrc.gov
Busse NC, Al-Ghazi MSAL, Abi-Jaoudeh N, et al. AAPM Medical Physics Practice Guideline 14.a: Yttrium-90 microsphere radioembolization. J Appl Clin Med Phys. 2024;25(2):e14157. doi:10.1002/acm2.14157. PubMed
Aberle S, Kenkel D, Becker AS, et al. Outpatient Yttrium-90 microsphere radioembolization: assessment of radiation safety and quantification of post-treatment adverse events causing hospitalization. Radiol Med. 2020;125(10):971-980. doi:10.1007/s11547-020-01180-4. PubMed
Gordon AC, Gates VL, White SB, et al. Yttrium-90 Radioembolization in the VX2 Rabbit Model: Radiation Safety and Factors Influencing Delivery Efficiency. J Vasc Interv Radiol. 2021;32(11):1569-1574. doi:10.1016/j.jvir.2021.08.008. PubMed
Salem R, Padia SA, Lam M, et al. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50(2):328-343. doi:10.1007/s00259-022-05956-w. PubMed
Mahvash A, Chartier S, Turco M, et al. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of Y-90 resin microspheres for the treatment of unresectable HCC: the DOORwaY90 study. BMC Gastroenterol. 2022;22(1):151. doi:10.1186/s12876-022-02204-1. PubMed
Kennedy AS, Brown DB, Fakih M, et al. Multidisciplinary Delphi Consensus on Safety of Combining Transarterial Radioembolization with Yttrium-90 Microspheres with Systemic Anticancer Agents. J Vasc Interv Radiol. 2024;35(9):1253-1267. doi:10.1016/j.jvir.2024.06.006. PubMed
American College of Radiology, ABS, ACNM, ARS, SIR, SNMMI. ACR–ABS–ACNM–ARS–SIR–SNMMI Practice Parameter for Radioembolization with Microsphere Brachytherapy Device (RMBD) for Treatment of Liver Malignancies. acr.org
International Commission on Radiological Protection. ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations. Ann ICRP. 2008;38(3). icrp.org